Sibware
1 year ago
$GMVD: Announces Closing of Public Offering
April 4, 2023 - 4:01 pm
Rehovot, Israel, April 04, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company”), a global leader in next-generation mobile health (mHealth) and digital health, today announced the closing of its public offering of 12,000,000 ordinary shares (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof), each sold to the public at a price of $0.80 (inclusive of the exercise price of the Pre-Funded Warrant) for gross proceeds of approximately $9.6 million, before deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,800,000 ordinary shares and/or Pre-Funded Warrants to cover over-allotments at the public offering price, less the underwriting discount.
The Company intends to use the net proceeds for general corporate purposes (including financing operations, capital expenditures and business development), the repayment in full of the April 2021 Financing Debentures, and potential mergers or acquisitions.
https://www.stocktitan.net/news/GMVD/g-medical-innovations-holdings-ltd-announces-closing-of-public-jppacofdrkqi.html
Invest-in-America
2 years ago
GMVD: Yet right now (in the A.H.), this proverbial 'DEAD CAT' may be bouncin' back to at least quasi-LIFE --- well, by a TINY bit, that is.
"Wake up, PALI!!! What's wrong??? PALI-wants-a-CBD-CRACKER, or something??? Get your ASK goin' --- before ya end-up a STINKY-PINKY, pussycat!!!"
ErnieBilco
2 years ago
So how exactly is this new patent different from the one they already have had for 4 years?
Systems and methods for vital signs monitoring with ear piece
Patent number: 10251603
Abstract: A vital signs monitoring system, the system including: (a) an ear device including: a curved body adapted to a shape of an ear, an upper end, a lower end, two opposite facing sides, a first side adapted to be proximal a skull and a second side adapted to be proximal an earlobe, the ear device including: (i) a temperature sensor adapted to sense a body temperature from a depression between a lower jawbone and skull; and (b) a control system, including a processor and a memory, configured and operable to control operation of the ear device, to collect signals received from at least one sensor including the temperature sensor, to process the signals to provide medically significant results.
Type: Grant
Filed: January 26, 2016
Date of Patent: April 9, 2019
Assignee: G-MEDICAL INNOVATIONS HOLDINGS LTD.
Inventors: Nir Geva, Yacov Geva
subslover
2 years ago
G Medical Innovations announces receiving notice of patent issuance from the USPTO for vital signs sensors
January 30 2023 - 06:15AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) (the “Company” or “G Medical Innovations”) today announced that it has received a patent issue notification from the United States Patent and Trademark Office (“USPTO”) for its monitoring products marketed in the United States. The patent, expected to be issued on February 7, 2023, Method and System for Vital Signs Monitoring with Earpiece, covers the vital signs monitoring system that the Company is developing using multiple sensing mechanisms to be used on different body locations. This vital sign monitoring system will potentially provide physicians more versatility in patients’ monitoring and would simplify in and out-patients’ monitoring.
Together with the two patents received in December 2022, G Medical Innovations continues to strengthen its position in the market with its unique technologies and services. The Company believes that obtaining these patents places the Company at the forefront of the industry and provides the Company a significant advantage over its competitors, specifically with regards to accurate monitoring of patients. This will potentially allow the Company to increase the market size for its products and its monitoring services.
This new patent adds to the Company’s patent portfolio, which includes six granted patents G Medical Innovations has received for its product (four in the United States and two in China).
The Company currently has three more patents which are pending approval from the USPTO.
About G Medical Innovations Holdings Ltd.:
G Medical Innovations Holdings Ltd. is a healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease, and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical-grade device that can transform almost any smartphone into a medical monitoring device, enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter and Monitoring Cardiac Telemetry Patch services, utilizing a multi-channel patient-worn biosensors, with algorithms for real time analysis and transmission that captures electrocardiography (i.e. ECG) data continuously, including QT Syndrome Prolongation Detection. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (i.e., IDTF) monitoring services and private monitoring services.
Visit https://gmedinnovations.com/.
Forward-Looking Statement:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical Innovations is using forward-looking statements when it discusses: the expected issuance and issuance date of a patent from the USPTO; the Company’s expectation that such patent will provide the Company with a significant advantage over its competitors; and the pending additional patents with the USPTO. Because such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical Innovations could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties. Except as otherwise required by law, G Medical Innovations undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.
Investors Relations Contact:
G Medical innovations
service@gmedinnovations.com
G Medical Innovations (NASDAQ:GMVD)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more G Medical Innovations Charts.